US-based biotechnology company Nimbus Therapeutics attracted $65m in funding yesterday from its existing shareholders, which include pharmaceutical firms Pfizer, GlaxoSmithKline, Eli Lilly and life sciences software developer Schrödinger.
All but Schrödinger invested through their respective corporate venturing units, Pfizer Venture Investments, SR One and Lilly Ventures. They were joined by Atlas Venture, Lightstone Ventures and private investor Bill Gates.
Nimbus Therapeutics is working on treatments in the areas of immunology, oncology and metabolic disease, using computer-driven drug discovery and development. The capital will enable Nimbus to accelerate and expand its pipeline.
The company previously closed a $43m series B round in 2015 co-led by Pfizer Venture Investments and Lightstone Ventures. Lilly Ventures and SR One also took part in the round alongside Atlas Venture and Gates.
Nimbus previously raised $24m in a 2011 series A round backed by SR One, Lilly Ventures, Atlas and Gates, who co-led a seed round of undisclosed size in 2011.